Cargando…
The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
Systemic sclerosis (SSc) is a rare autoimmune condition with complex pathogenesis characterized by a heterogeneous presentation and different disease courses. Fibrosis of multiple organs including the lungs favored by inflammation and vasculopathy is the hallmark of SSc. SSc-associated interstitial...
Autores principales: | Boleto, Gonçalo, Avouac, Jérôme, Allanore, Yannick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801639/ https://www.ncbi.nlm.nih.gov/pubmed/35111241 http://dx.doi.org/10.1177/1759720X211066686 |
Ejemplares similares
-
The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
por: Liang, Minrui, et al.
Publicado: (2022) -
Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease
por: Wilfong, Erin M., et al.
Publicado: (2021) -
Interstitial lung disease pathology in systemic
sclerosis
por: Konopka, Kristine E., et al.
Publicado: (2021) -
Systemic sclerosis associated interstitial lung disease: a survey of
current practices in France
por: Nicolas, Amélie, et al.
Publicado: (2023) -
Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)